正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06632717
海外临床试验导航
肝癌
帮助用户按 HCC、HBV 相关、BCLC、免疫治疗、VEGF/TKI 等方向检索海外公开临床试验。
Synced trials
当前同步到的治疗类试验
以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。
招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。
状态
全部
试验阶段
全部
治疗类型
全部
国家/地区
全部
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07620574
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT05738980
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06461624
Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06482801
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06676982
Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07547553
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06883539
A Phase I Study of LXP1788 Injection with Advanced Solid Tumors.
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06910657
IDOV-Immune for Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07689175
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06724263
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
正在招募
Phase 2
生物制剂放疗
clinicaltrials.gov
NCT04430452
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07070076
A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Therapy) Therapy and Hepatic Arterial Infusion Chemotherapy (Hepatic Artery Infusion Chemotherapy) for Potentially Resectable Intermediate and Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06646198
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07132515
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06685354
Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06796803
Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05970666
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07413354
Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07352007
Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT04499833
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06261125
Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT06166576
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06737913
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06584071
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05971628
Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07691762
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
正在招募
Phase 2
器械药物
clinicaltrials.gov
NCT07122089
Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT06201065
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07282509
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05516628
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06902389
A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07535840
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06096779
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07310173
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06239194
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07410494
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07657273
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
即将招募
Phase 1, Phase 2
联合产品
clinicaltrials.gov
NCT07187284
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
正在招募
Phase 3
药物
clinicaltrials.gov
NCT07267806
Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC
正在招募
Phase 4
药物手术/操作
clinicaltrials.gov
NCT06594744
Endoscopic Variceal Ligation vs Carvedilol for the Prevention of First Esophageal Variceal Bleeding in Patients With HCC
正在招募
Phase 3
手术/操作
clinicaltrials.gov
NCT07594340
HAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03812874
A Study of PTX-9908 Injection for Non-resectable HCC with TACE
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07350070
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06687941
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07337421
Efcacy and Safety of Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With mFOLFOX in Hepatocellular Carcinoma With High-risk Recurrence Factors
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06530784
Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06958484
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06689540
Mts105 for Advanced Hepatocellular Carcinoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05286320
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06109272
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
即将招募
Phase 3
药物其他
clinicaltrials.gov
NCT06089369
Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06867432
Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma
即将招募
Phase 3
药物手术/操作放疗
clinicaltrials.gov
NCT05718232
SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT05476432
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06617000
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07123545
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06034977
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06478927
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03539822
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06812039
HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT06178198
Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06740370
TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT04380545
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
正在招募
Phase 1, Phase 2
生物制剂手术/操作放疗
clinicaltrials.gov
NCT03942328
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07324473
Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07369505
Sapu003 in Advanced mTOR-sensitive Solid Tumors
正在招募
Phase 3
联合产品
clinicaltrials.gov
NCT06492395
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
即将招募
Phase 4
药物放疗
clinicaltrials.gov
NCT07668570
SBRT Plus QL1706 as Second-Line Therapy for Hepatocellular Carcinoma
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05750329
Liver Transplantation With Two-stage Liver Resection in Unresectable Liver Cancer , Metastases or Emd-stage Liver Disease (LTLR-LC)
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT04745390
Standard Versus Radiobiologically-Guided Dose Selected SBRT in Liver Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04803318
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
即将招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT06089382
A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07543783
Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06280105
A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07052253
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
正在招募
Phase 4
药物放疗
clinicaltrials.gov
NCT07059494
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06870942
Efficacy and Safety of Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05887661
Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
即将招募
阶段未标明
联合产品
clinicaltrials.gov
NCT07268131
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06622031
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
即将招募
Phase 2
药物其他
clinicaltrials.gov
NCT07537972
Denosumab Strategy for Liver Cancer With Bone Metastases
正在招募
Phase 2, Phase 3
药物手术/操作
clinicaltrials.gov
NCT06844357
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07557251
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
正在招募
Phase 3
联合产品
clinicaltrials.gov
NCT06485466
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06248554
Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07275073
JMT106 Injection in the Treatment of Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07014150
Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06852820
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06375317
HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06446154
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07243691
Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
即将招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT07480382
Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06904170
Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05594927
Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)
即将招募
Phase 1
联合产品
clinicaltrials.gov
NCT06990620
TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04823403
Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT04988945
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05882370
TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07078305
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07175441
Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07201064
A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT07039201
A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07100392
Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
正在招募
Phase 1, Phase 2
诊断检测药物
clinicaltrials.gov
NCT06726161
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05797805
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07223424
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06434480
SBRT in HCC With Oligoprogression on First-line Immunotherapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05992584
Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07012798
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT04221893
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05155189
A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05257590
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07209813
GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07337460
Efficacy and Safety of Icaritin Combined With mFOLFOX in Postoperative HCC With High-risk Recurrence Factors
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07115550
A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07475026
A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06961617
Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06519578
Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular Carcinoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07479485
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT05377034
Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05669339
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07239245
Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo
正在招募
Phase 2
药物
clinicaltrials.gov
NCT03899428
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07327034
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06978933
FGF19 Overexpression Combination Unified Study in HCC-19
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07493668
Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT06811116
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05842174
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT05613478
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06822985
QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06904014
Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT07500220
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT06766643
Stereotactic Radiosurgery Versus Radiofrequency Ablation for Primary Liver Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05201404
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
即将招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07511504
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06900478
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06420440
Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06526104
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06742892
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05417932
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06133062
Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05620771
Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07192848
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07151326
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy
即将招募
EARLY / Phase 1
生物制剂药物
clinicaltrials.gov
NCT06364800
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06880523
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07239986
A Phase 2 Study of BB102 in Patients With Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06498622
Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT05803928
Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07077798
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT05844046
Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06930573
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT06590246
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06389422
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06397222
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT05488522
SBRT With Atezo/Bev for HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07176650
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06915753
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06196775
A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06954467
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05862337
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06535737
A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05985798
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
正在招募
Phase 4
药物
clinicaltrials.gov
NCT06311929
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06265350
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
即将招募
Phase 3
手术/操作放疗
clinicaltrials.gov
NCT07381660
SBRT Versus Surgical Resection for Small HCC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06860490
HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT05917431
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06999707
Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
即将招募
阶段未标明
器械药物
clinicaltrials.gov
NCT07596134
Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT04150744
RFA Plus Carrizumab vs Carrizumab Alone for HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05937295
FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
正在招募
Phase 1, Phase 2
生物制剂药物放疗
clinicaltrials.gov
NCT06725121
Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06645314
Study on the Safety and Efficacy of BST06 Injection in the Treatment of Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06914648
The Dragon PLC Trial (DRAGON-PLC)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06254248
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07148050
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07242417
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07639138
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06427941
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06789757
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06143579
A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
即将招募
阶段未标明
药物其他
clinicaltrials.gov
NCT07350824
Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07482059
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06454578
Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
正在招募
Phase 2, Phase 3
生物制剂药物
clinicaltrials.gov
NCT07490262
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06789848
Ligufalimab and Cadonilimab in Advanced Liver Cancers
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07119931
A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05440864
Durvalumab and Tremelimumab in Resectable HCC
正在招募
Phase 4
手术/操作
clinicaltrials.gov
NCT06717919
HOPE Against Cancer Recurrence in HCC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT04472767
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04770207
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT06364787
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07197554
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06400160
Clinical Trial of TB511 in Advanced Solid Tumors
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT03895359
Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07543510
Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT04803994
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
正在招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT03259867
Combination of TATE and PD-1 Inhibitor in Liver Cancer
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06205472
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06741020
Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07154082
Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06508307
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06061276
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05897138
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05690048
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06530251
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06527495
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
正在招募
Phase 1
器械药物
clinicaltrials.gov
NCT06710223
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07075419
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07238881
Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT05003895
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06551272
Microbiota Modification for Immuno-oncology in Hepatocellular Carcinoma
正在招募
Phase 4
药物
clinicaltrials.gov
NCT07150624
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
正在招募
Phase 3
联合产品
clinicaltrials.gov
NCT05738616
Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06609876
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT05652920
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
正在招募
阶段未标明
其他手术/操作
clinicaltrials.gov
NCT06542796
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07106827
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06884982
An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT04777942
Neo-TACE-HAIC for High-risk BCLC A Stage HCC (NeoconceptA)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06339424
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06538935
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06060847
Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05920863
Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT06595108
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06031285
Perioperative Sintilimab Plus Bevacizumab Biosimilar and TACE-HAIC for HCC Patients With PVTT: A Phase-2 Clinical Trial
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT05992220
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07157969
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07515469
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07157306
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06027086
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05468359
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT06995105
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04134559
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
正在招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT06418659
A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT02174549
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06005740
A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer
即将招募
阶段未标明
其他放疗
clinicaltrials.gov
NCT05602974
Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07584018
The DoHAICs Study Expansion Phase
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT06114082
TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06301399
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06893887
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06475287
HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT05620706
Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT05791448
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06858813
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05482516
Evaluating Novel Therapies in ctDNA Positive GI Cancers
正在招募
Phase 2
药物手术/操作放疗
clinicaltrials.gov
NCT07062055
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT07246668
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
正在招募
Phase 3
生物制剂
clinicaltrials.gov
NCT05489289
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06581315
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05596630
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06069947
SALT for Liver Cirrhosis With HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06789198
Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
即将招募
Phase 3
联合产品药物
clinicaltrials.gov
NCT07356037
Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05751343
Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT06707233
Y-90 SIRT for Unresectable HCC Larger Than 7cm
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07589244
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07317414
β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT06994572
Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma
正在招募
Phase 1
联合产品
clinicaltrials.gov
NCT04952272
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Release for Advanced Solid Tumors
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05629845
Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06363006
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
正在招募
阶段未标明
生物制剂
clinicaltrials.gov
NCT05926726
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07192185
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06294548
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT05444478
Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07274774
SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07099274
Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07230314
Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06518434
A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07518706
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06066138
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06309485
Phase 2 Study of WGI-0301 for Advanced HCC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06695026
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07179900
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06041477
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
正在招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT05608213
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07463248
PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07684040
A Study of Combination Therapy in Patients With Resectable Liver Cancer
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT03093688
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT05984511
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05901519
A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07064668
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
即将招募
Phase 3
药物手术/操作
clinicaltrials.gov
NCT07537946
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07514429
Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06362369
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06172205
Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
正在招募
Phase 1
器械药物
clinicaltrials.gov
NCT05701488
SIRT With Tremelimumab and Durvalumab for Resectable HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07150377
A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂联合产品
clinicaltrials.gov
NCT04282044
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT07227012
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
即将招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06592612
Second-line Systemic Therapy Combined with SBRT for HCC with Oligoprogression After Standard First-line Systemic Treatment
正在招募
Phase 1
生物制剂药物手术/操作
clinicaltrials.gov
NCT05092373
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
正在招募
Phase 2, Phase 3
药物手术/操作放疗
clinicaltrials.gov
NCT07293468
Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT07644208
PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy
正在招募
EARLY / Phase 1
药物手术/操作
clinicaltrials.gov
NCT07295262
NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07580261
YMN-A02 for Advanced Primary Hepatocellular Carcinoma.
即将招募
Phase 3
器械手术/操作
clinicaltrials.gov
NCT06779461
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07018947
Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07514455
Regorafenib After Treatment Failure of First Line Immune Checkpoint Inhibitor Treatment in Advanced Hepatocellular Carcinoma Patients
即将招募
阶段未标明
放疗
clinicaltrials.gov
NCT06708650
Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06313190
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07010497
A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06349980
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06698250
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04204850
Cabozantinib to Treat Recurrent Liver Cancer Post Transplant
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05408221
the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07376707
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06618664
A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT05908916
Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT07521852
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06609863
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07070518
Study of GV20-0251 in Participants With Solid Tumor Malignancies
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07164313
A Study of ZW251 in Participants With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06360042
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07291076
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
正在招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT06904196
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07252323
A Single-arm Phase II Clinical Study Investigating the Safety and Efficacy of Carbon Ion Radiotherapy in Patients With Hepatocellular Carcinoma Previously Treated With Transarterial Radioembolization (TARE)
正在招募
Phase 3
手术/操作
clinicaltrials.gov
NCT07322848
DEB-TACE vs cTACE in HCC After TIPS
即将招募
Phase 3
生物制剂药物
clinicaltrials.gov
NCT06680258
A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06553885
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
即将招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT07281664
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07226063
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04745403
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07027436
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06954116
Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06909708
SIRT Versus cTACE for Unresectable HCC (CHANCE2506)
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06526338
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06422403
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
正在招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT05323201
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07128251
A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)
正在招募
Phase 3
药物其他
clinicaltrials.gov
NCT05317819
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06546280
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04248569
DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07131501
A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05366829
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06624098
Early Transjugular Intrahepatic Portosystemic Shunt for Advanced Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06935175
A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05412589
mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC
即将招募
Phase 1, Phase 2
手术/操作
clinicaltrials.gov
NCT07587034
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07560488
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06374485
Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard Treatment
即将招募
Phase 1, Phase 2
器械药物
clinicaltrials.gov
NCT07522411
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
正在招募
Phase 1
器械药物
clinicaltrials.gov
NCT06044506
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
即将招募
Phase 2
药物其他
clinicaltrials.gov
NCT06512467
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07314372
FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06644937
Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT04634357
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07682272
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
即将招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06836778
Comparative Study of Carvedilol Monotherapy Versus Combination Therapy With Endoscopic Variceal Ligation (EVL) for Primary Prophylaxis of Variceal Bleeding in Patients With Hepatocellular Carcinoma With High-Risk Esophageal Varices
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07018518
PIN in Combination With Anti-PD1 in Previously Treated Primary Hepatocellular Carcinoma
正在招募
Phase 2
放疗
clinicaltrials.gov
NCT06828380
A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT03897543
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05078047
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT06349317
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06582017
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05195294
Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05954897
Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma
正在招募
Phase 2, Phase 3
联合产品
clinicaltrials.gov
NCT07302919
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
正在招募
Phase 3
手术/操作
clinicaltrials.gov
NCT03368651
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07419841
A Phase 1 Study of the Safety and Tolerability of CTX-10726
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT06795022
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07392866
A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT07628751
A Study of Standard Of Care Versus Radio Ablation in Early Stage HCC
正在招募
Phase 1
药物手术/操作
clinicaltrials.gov
NCT06470256
Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06891742
Phase I Study of OriC902 in Treatment of Advanced HCC
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07623369
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT07657897
The Impact of Anaesthesia on Inflammation and NETosis in Hepatocellular Carcinoma Resection
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT06198296
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
即将招募
Phase 4
手术/操作
clinicaltrials.gov
NCT02785380
Laparoscopic Surgery VS RFA for Recurrent HCC
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT06007846
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07627191
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05331911
Impact of Propofol-Based Total Intravenous Anesthesia Versus Anesthesia With Sevoflurane on Long-term Outcomes With Patients Undergoing Elective Excision of Primary Liver Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07391839
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05185739
Perioperative Pembrolizumab and Lenvatinib in Resectable Hepatocellular Carcinoma (HCC)
正在招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07594964
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT04601428
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06515314
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06487663
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
即将招募
Phase 4
药物其他
clinicaltrials.gov
NCT06923176
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07489976
IIT2025-03-YANG-LIFT-HCC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05440708
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07494435
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06694636
Intravascular Radiofrequency Ablation of Sympathetic Nerves for the Treatment of Hepatocellular Carcinoma
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT07483359
Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT05096715
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07487402
Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT05475613
Downstaging Protocol Containing Immunotherapy for HCC Beyond the Milan Criteria Before Liver Transplantation
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07536789
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04114136
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
即将招募
Phase 4
药物手术/操作
clinicaltrials.gov
NCT06311916
Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model.
即将招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT07690683
Patients With Hepatocellular Carcinoma (HCC)
即将招募
Phase 4
药物
clinicaltrials.gov
NCT07160361
Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07493044
An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07553767
Efficacy and Safety of Pegylated Interferon Alpha-2β in Patients With Hepatitis B-related Hepatocellular Carcinoma After Radical Resection
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06070636
bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT05304481
Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07328009
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
正在招募
Phase 1
联合产品
clinicaltrials.gov
NCT04587739
Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07348211
First in Human Study of SIM0610 in Solid Tumors
即将招募
Phase 1, Phase 2
生物制剂药物
clinicaltrials.gov
NCT06641453
CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07077356
Application of mRNA Vaccine in Liver Transplantation for Hepatocellular Carcinoma
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05994859
SIRT for Potentially Resectable HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06986785
A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
即将招募
Phase 1
生物制剂药物
clinicaltrials.gov
NCT07077369
WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07297654
First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07501351
Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06558227
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT03198546
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT04912765
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
正在招募
Phase 2
联合产品
clinicaltrials.gov
NCT06904183
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
正在招募
Phase 2
生物制剂药物手术/操作
clinicaltrials.gov
NCT07174570
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
正在招募
Phase 3
药物
clinicaltrials.gov
NCT03949231
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06090656
Bevacizumab in Combination With Sintilimab Versus Transcatheter Arterial Chemoembolization for the Treatment of Intermediate Stage Hepatocellular Carcinoma (Beyond Up-To-Seven Criteria)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06215651
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07430202
A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06999694
Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC
正在招募
Phase 2
联合产品药物
clinicaltrials.gov
NCT05057845
Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT07042919
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
即将招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT07657416
NK521 in the Treatment of Advanced Solid Tumors
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05168163
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
即将招募
Phase 3
药物
clinicaltrials.gov
NCT07461675
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
即将招募
Phase 2
联合产品
clinicaltrials.gov
NCT07363512
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT06550921
Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
药物放疗
clinicaltrials.gov
NCT06349044
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
即将招募
EARLY / Phase 1
药物
clinicaltrials.gov
NCT07446257
THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT06560827
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
正在招募
Phase 2
手术/操作
clinicaltrials.gov
NCT06819566
Prophylactic Endoscopic Variceal Ligation in Patients With High-risk Esophageal Varices Receiving Atezo/Bev for HCC
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05024214
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT06762782
Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06636435
A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05223816
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07540832
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT06253598
Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma
正在招募
Phase 2
生物制剂药物其他
clinicaltrials.gov
NCT07219459
Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06607107
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07537777
Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy
正在招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT05919264
FOG-001 in Locally Advanced or Metastatic Solid Tumors
正在招募
Phase 2
生物制剂
clinicaltrials.gov
NCT05733598
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT05528952
Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07331883
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
正在招募
EARLY / Phase 1
生物制剂
clinicaltrials.gov
NCT06652243
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06397235
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07252661
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07047586
Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab
即将招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT05976568
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
正在招募
Phase 1
生物制剂
clinicaltrials.gov
NCT04147078
Personalized DC Vaccine for Postoperative Cancer
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06363825
A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
正在招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT05451043
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
即将招募
Phase 2
生物制剂药物
clinicaltrials.gov
NCT06984718
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
即将招募
Phase 2, Phase 3
药物手术/操作放疗
clinicaltrials.gov
NCT06739317
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05208762
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07412054
Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07365839
Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07495579
Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)
正在招募
Phase 3
药物
clinicaltrials.gov
NCT06921785
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07224568
Cytokine Armored GPC3 Specific Chimeric Antigen Receptor Expressing T-cells in Adults With Solid Tumors
正在招募
Phase 2, Phase 3
药物
clinicaltrials.gov
NCT07285850
The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD
正在招募
Phase 2
药物
clinicaltrials.gov
NCT04615143
Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT06742424
PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC
即将招募
Phase 2, Phase 3
器械药物
clinicaltrials.gov
NCT07309419
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
正在招募
Phase 3
药物
clinicaltrials.gov
NCT05608200
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
正在招募
Phase 1, Phase 2
生物制剂
clinicaltrials.gov
NCT04864054
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07053072
PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma.
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07487662
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
即将招募
阶段未标明
其他手术/操作
clinicaltrials.gov
NCT07537959
Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases
正在招募
Phase 4
药物手术/操作
clinicaltrials.gov
NCT07405086
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
正在招募
Phase 1
药物放疗
clinicaltrials.gov
NCT07075120
Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT06609850
The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06664996
Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT
正在招募
Phase 1
药物
clinicaltrials.gov
NCT07478302
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT04806464
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07243951
Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
即将招募
阶段未标明
药物其他
clinicaltrials.gov
NCT07618546
A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors
正在招募
Phase 3
药物放疗
clinicaltrials.gov
NCT06841172
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
即将招募
Phase 1
生物制剂
clinicaltrials.gov
NCT07558200
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06326502
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07422753
A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05203120
A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma
正在招募
Phase 3
药物其他手术/操作
clinicaltrials.gov
NCT06371157
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06406634
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
即将招募
Phase 3
药物
clinicaltrials.gov
NCT06841185
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
即将招募
Phase 1, Phase 2
药物
clinicaltrials.gov
NCT07636785
A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05176483
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
正在招募
Phase 4
药物
clinicaltrials.gov
NCT05185505
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07327788
QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06478693
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06492408
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.
即将招募
Phase 1
药物
clinicaltrials.gov
NCT07583316
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT05975463
Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy
正在招募
Phase 3
药物手术/操作放疗
clinicaltrials.gov
NCT07186621
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
正在招募
Phase 1, Phase 2
联合产品其他手术/操作
clinicaltrials.gov
NCT07282184
Multimodal Deep Learning for Postoperative Liver Cancer Risk Stratification and Intervention
正在招募
Phase 1
基因治疗
clinicaltrials.gov
NCT07364357
A Phase I Study of CREPT-618 in Locally Advanced HCC
即将招募
Phase 2
药物
clinicaltrials.gov
NCT07687914
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
正在招募
阶段未标明
手术/操作放疗
clinicaltrials.gov
NCT04996914
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT07312292
Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT05718492
A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
正在招募
阶段未标明
手术/操作
clinicaltrials.gov
NCT05433467
CT-guided Localization for Micro Hepatocellular Carcinoma Before Surgical Resection
正在招募
Phase 2
药物
clinicaltrials.gov
NCT06244225
HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
即将招募
Phase 4
药物手术/操作
clinicaltrials.gov
NCT06496815
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy
正在招募
Phase 3
手术/操作
clinicaltrials.gov
NCT04868149
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
即将招募
阶段未标明
药物
clinicaltrials.gov
NCT07253220
TAF Monotherapy Versus ETV Combined With TAF on the Efficacy and Prognosis of Immunotherapy for Hepatitis B-Related Hepatocellular Carcinoma
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07324824
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
即将招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT06896396
Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular Carcinoma
正在招募
阶段未标明
药物手术/操作
clinicaltrials.gov
NCT07408804
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
正在招募
Phase 4
手术/操作
clinicaltrials.gov
NCT06353126
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
正在招募
Phase 1, Phase 2
药物手术/操作
clinicaltrials.gov
NCT06911255
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06487559
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05341557
A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
正在招募
Phase 2
药物放疗
clinicaltrials.gov
NCT06823375
SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis
正在招募
Phase 1
药物
clinicaltrials.gov
NCT05581004
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
即将招募
Phase 2
生物制剂
clinicaltrials.gov
NCT06563947
Single Arm Clinical Trial (Gut Microbiota and HCC)
正在招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07105748
HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)
正在招募
Phase 2
药物
clinicaltrials.gov
NCT07111546
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
正在招募
Phase 1
药物
clinicaltrials.gov
NCT06764836
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
正在招募
阶段未标明
药物
clinicaltrials.gov
NCT06251115
Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC
正在招募
阶段未标明
放疗
clinicaltrials.gov
NCT05727787
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
正在招募
Phase 2
药物其他
clinicaltrials.gov
NCT07276100
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
即将招募
Phase 2
药物手术/操作
clinicaltrials.gov
NCT07168668
Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment
第 1 页
没有符合当前筛选条件的试验。
Subtypes
建议拆分方向
hepatocellular carcinoma / HCCadvanced liver cancerunresectable HCCHBV-related HCCBCLC stageimmunotherapyVEGFTKI
Keyword guide
这些关键词怎么理解
| 术语 | 中文意思 | 对找临床试验有什么用 |
|---|---|---|
| 肝细胞癌 / HCC | 最常见的原发性肝癌类型。 | 海外试验常用 hepatocellular carcinoma 或 HCC，而不只写 liver cancer。 |
| 不可切除 / Unresectable | 通常指无法通过手术完整切除，具体由医生评估。 | 很多系统治疗试验会限定 unresectable HCC。 |
| HBV-related HCC | 和乙肝相关的肝细胞癌。 | 部分试验会关注 HBV 状态、抗病毒治疗或肝功能要求。 |
| BCLC stage | 肝癌常用分期体系之一。 | 试验可能会限定 BCLC B 或 C 等阶段。 |
| Immunotherapy | 免疫治疗方向，例如 PD-1、PD-L1、CTLA-4 等。 | 可以找免疫联合 VEGF/TKI 或二线免疫治疗试验。 |
| Child-Pugh | 评估肝功能状态的评分。 | 很多肝癌试验会要求 Child-Pugh A 等条件。 |
Recruitment status
常见招募状态
| Recruiting | 正在招募，可能仍可申请参加。 |
| Not yet recruiting | 尚未开始招募，可关注后续开放时间。 |
| Active, not recruiting | 试验仍在进行，但通常不再招新患者。 |
| Completed | 试验已经完成。 |
| Terminated | 试验提前终止。 |
| Unknown | 公开页面上的状态不明确或未及时更新。 |
Before contact
联系前准备资料
- 病理诊断报告
- 影像报告：CT / MRI / PET-CT
- 既往治疗记录
- 用药历史
- 基因检测报告
- 最近血液检查结果
- 出院小结
- 主治医生英文病情摘要，如果有
- 护照和签证情况，如果考虑出国
Filters
搜索时重点关注
- Recruiting / Not yet recruiting
- Location
- Age
- Phase
- Inclusion Criteria
- Exclusion Criteria
- Prior treatments
- Biomarker / mutation requirements
- ECOG performance status
- 是否接受 international patients
- 是否需要长期停留在试验所在地
- 费用、保险、翻译、住宿和陪护安排
Ask your doctor
可以带去问医生的问题
- 我的病理类型是否符合这个试验？
- 我之前用过的药会不会影响入组？
- 我是否需要做基因检测？
- 这个试验是几期？主要目的是什么？
- 参加试验会不会影响当前治疗？
- 如果去国外参加，风险和成本大概有哪些？
- 研究团队是否接受海外患者？
请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。